Post written by: BioTech Health X
You May Also Like
Galectin (GALT) Reports Improved Financial Performance in Q3 2024
- BioTech Health X
- December 31, 2024
- 3 minute read
Table of Contents Hide Advancing Breakthrough Therapies: Belapectin and the NAVIGATE TrialFinancial Strength and Operational FocusStrategic Vision for…
ABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study
- BioTech Health X
- November 14, 2024
- 3 minute read
Table of Contents Hide The Burden of nAMD and the Promise of Gene Therapy Efficacy and Safety in…
MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
- BioTech Health X
- September 7, 2021
- 3 minute read
Biopharma MacroGenics, Inc. (NASDAQ: MGNX) announced that the final overall survival (OS) analysis did not demonstrate a statistically…
Aclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune Diseases
- BioTech Health X
- November 20, 2024
- 3 minute read
Table of Contents Hide Promising Pipeline Focused on Unmet Medical Needs Strategic Licensing Agreements Expanding the Pipeline Positive…
Istari Oncology Begins Phase 1 / Phase 2 Sub-Study To Evaluate PVSRIPO in Head and Neck Cancer Patients
- BioTech Health X
- August 17, 2021
- 3 minute read
Istari Oncology, Inc., a clinical-stage biotechnology firm focused on unique immunotherapy systems for the treatment of strong lumps,…
Aethlon (AEMD) Reports Q1 2024 Results and Advances Cancer and Virus Treatment Trials
- BioTech Health X
- November 7, 2024
- 2 minute read
Table of Contents Hide Clinical Advancements for Hemopurifier® in OncologyStrong Financials and Cost Efficiency Drive Q1 PerformanceExpanding Research…